uploads///Ocrevus_

Roche’s Ocrevus Is a Highly Effective Option for MS Treatment

By

Apr. 12 2018, Updated 1:20 p.m. ET

Ocrevus

Roche’s (RHHBY) Ocrevus, approved by the FDA in March 2017, is targeted at the treatment of relapsing and primary progressive forms of multiple sclerosis (or MS). The drug has demonstrated superior efficacy in reducing relapses and slowing the worsening of the disability caused by the disease. 

Ocrevus was also approved in the European Union (or EU) for these two forms of MS in January 2018. In total, the drug has been approved in more than 50 countries.

Article continues below advertisement

With its rising market share, Ocrevus is a highly effective treatment option for MS, offering a highly favorable risk-benefit profile as demonstrated in three Phase 3 studies of the drug. In spite of the available therapies for MS, some patients with relapsing forms of MS continue to experience disease activity and the worsening of their disability. Patients with primary progressive MS with no approved treatment experienced a faster accumulation of disability. Given every six months, Ocrevus has the potential to transform therapy for both these forms of MS.

Sales growth

In 2017, Roche’s pharmaceutical division’s sales rose 5% to 41.2 billion Swiss francs. Ocrevus, Tecentriq, and Alecensa contributed a combined 1.4 billion francs in new sales, representing 65% of the division’s growth. In 2017, Ocrevus registered sales of 869 million francs. Globally, by the end of 2017, 30,000 people had been treated with Ocrevus.

Ocrevus has achieved more than a 5% market share in the United States, and Roche expects further gains in the drug’s market share in the country in 2018 on the back of an increase in its prescriber base and insurance coverage.

In the next part of the series, we’ll take a look at Biogen’s Spinraza.

Advertisement

More From Market Realist

  • Angels and Tomboys creators Mallory Iyana and Madison Star
    Miscellaneous
    'Shark Tank' Angels and Tomboys—e-Commerce to Brick-and-Mortar
  • David and Joanna Parker of Yumble
    Miscellaneous
    Meal Subscription Service Yumble Didn’t Tumble After ‘Shark Tank’
  • People looking at data on a laptop
    Miscellaneous
    Best Penny Stocks for Investors to Buy Below $5
  • Amish men and children in a buggy
    Miscellaneous
    Yes, Amish and Mennonite Communities Pay Taxes — Here's How
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.